Literature DB >> 23921191

Posterior reversible encephalopathy syndrome: a noteworthy syndrome in end-stage renal disease patients.

Eleni Ermeidi1, Olga Balafa, Giorgos Spanos, Anastasia Zikou, Maria Argyropoulou, Kostas C Siamopoulos.   

Abstract

BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiologic entity characterized by headache, visual disturbances, seizures, and the presence of edema on MRI scan, predominantly in the posterior white matter. Regarding end-stage renal disease (ESRD) and PRES, only a few cases of children on peritoneal dialysis (PD) and adults on hemodialysis have been described in the literature. CASES: We report 4 cases of adult patients on PD who presented with PRES, all of which were due to hypertension and inadequate management of fluid balance. The patients expressed typical PRES symptoms such as headache, visual disorders, and tonic/clonic seizures. The patients recovered completely and the MRI lesions disappeared after strict control of volume status.
CONCLUSION: Nephrologists should be aware of the syndrome, especially when they manage hypertensive ESRD patients not compliant with the fluid and diet restrictions. MRI scan is the only diagnostic tool for defining the syndrome. Early diagnosis is important, since complete remission is achieved after appropriate treatment.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23921191     DOI: 10.1159/000353731

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  2 in total

1.  Posterior Reversible Encephalopathy Syndrome in Two Omani Children with Underlying Renal Diseases.

Authors:  Mohamed A El-Naggari; Dana Al-Nabhani; Ibtisam El-Nour; Alaa El-Manzalawy; Anas-Alwogud A Abdelmogheth
Journal:  Sultan Qaboos Univ Med J       Date:  2015-08-24

2.  Clinical characteristics and outcomes of patients admitted to hospitals for posterior reversible encephalopathy syndrome: a retrospective cohort study.

Authors:  Abbas Alshami; Asseel Al-Bayati; Steven Douedi; Mohammad A Hossain; Swapnil Patel; Arif Asif
Journal:  BMC Neurol       Date:  2021-03-09       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.